Biotricity Inc. (Biotricity) announces high demand for its latest breakthrough device, Biotres Pro. This device is easy to wear, resulting in excellent patient compliance and a higher selling price. Biotres Pro is expected to raise the average subscription price by over 32%.

Biotricity Inc. (Biotricity) announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes. This cardiac monitoring pilot program is poised to showcase the revolutionary impact of Biotricity’s technology suite.

Biotricity Inc. (Biotricity) continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues.  There are over 1,000 neurological disorders and over 100 million Americans suffering from at least 1 neurological issue. Alzheimer’s, Parkinsons, and other dementias are just a few such conditions that lead to increased cardiovascular risk. Many of these patients are screened late, leading to an increase in costs and higher patient risk. Biotricity is focused on providing earlier screenings to patients with co-morbidities, reducing costs while improving the quality of care.

Biotricity Inc. (Biotricity) continues its strategic expansion with the announcement of its latest partnership with yet another leading Group Purchasing Organization (GPO). GPOs streamline purchasing processes for medical providers and systems. With this latest partnership, Biotricity’s GPO partners collectively manage the buying needs of 9 out of every 10 hospitals in the U.S. Moreover, they wield immense purchasing power, totaling $264 billion.

Biotricity Inc. (Biotricity) announces the expansion of its Cardiac AI Cloud platform: the company is building a cardiac AI clinical model which distills important information to support clinician in cases that require clinical intervention or review. The company expects to file an FDA clearance for its clinical model by the end of the year.

Biotricity Inc. (“Biotricity”) today announced its partnership with another of the nation’s top Group Purchasing Organizations (GPOs). This strategic move solidifies Biotricity’s presence in the healthcare landscape and broadly expands market access for the Company in 2024. Biotricity now has access to over half the hospitals in the US, with a network of over 3,000 hospitals, through these two major GPOs which are responsible for over US $160 billion in purchasing power.